Mandate

Vinge advises Bilia on refinancing

March 27, 2024 Banking and Finance

Vinge had advised Bilia AB (publ) in connection with the SEK 2.3 billion refinancing of its existing revolving loan and credit facilities.

The new credit facility amounts to SEK 2,300 million, with a split of SEK 1,700 million in revolving loans and SEK 600 million in overdraft loans. The revolving loans have a tenor three years with an extension option (one plus one years) upon the lenders approval. DNB and Nordea are the original lenders under the new credit facility.

Together with outstanding unsecured bonds of SEK 1,300 million, in relation to which Vinge has also advised Bilia, the credit facility constitutes a significant part of Bilia’s long-term core financing.

Vinge’s team consisted of Anders Strid, Lionardo Ojeda, Sofia Haggren and Frithiof Hallgren Wallin.

Related

Vinge has advised Oncopeptides in connection with its rights issue

Vinge has advised Oncopeptides AB (publ) in connection with a fully guaranteed rights issue which will provide Oncopeptides with proceeds of approximately SEK 150 million before deduction of transaction costs.
August 28, 2025

Vinge advises Main Capital and Unik in connection with the acquisition of LEB System Aktiebolag

Vinge has advised Unik International ApS (“Unik”), a Danish Housing and Property Management software provider, in connection with the acquisition of LEB System Aktiebolag. The synergistic acquisition is expected to complement and expand Unik’s offering and has a strong strategic fit with Unik and is in line with the company’s internationalization strategy in the Nordic Property Management software market.
August 28, 2025

Vinge has advised Xspray Pharma in connection with its rights issue and debt refinancing

Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 130 million before transaction costs, with an over-allotment issue of approximately SEK 20 million, and refinancing of an existing loan.
August 28, 2025